Reuters

FDA approves Biogen's oral MS drug, Tecfidera

WASHINGTON (Reuters) - U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with ...
FiercePharma

Biogen faces multibillion-dollar Tecfidera loss if Mylan wins latest patent threat

Cash cow Tecfidera has been pumping out blockbuster sales as Biogen plows ahead with pricey Alzheimer's trials and scouts for new pipeline assets. But what if those sales took a big hit early next ...
Nasdaq

Biogen Falls on Patent Loss of MS Drug Tecfidera to Mylan

Shares of Biogen Inc. BIIB declined 7.5% on Thursday after the U.S. District Court for the Northern District of West Virginia invalidated a patent related to its blockbuster multiple sclerosis (MS) ...
Reuters

Biogen receives patent until 2028 for Multiple Sclerosis drug Tecfidera

(Reuters) - Biogen Idec Inc said on Tuesday it has been granted a new patent that will help protect the market exclusivity of its multiple sclerosis drug Tecfidera until 2028. The new patent covers ...
KING5

FDA approves oral multiple sclerosis drug, Tecfidera

The FDA has approved a new multiple sclerosis drug made by Biogen Idec Inc. that's viewed as the best in a new wave of treatments for the disease. The drug, Tecfidera, is taken orally and works by ...
FiercePharma

Biogen scores FDA nod for Tecfidera follow-up Vumerity as MS threats linger

Biogen's multiple sclerosis business has been treading water and its best-selling med, Tecfidera, might just run up against early generics. But now, the company has its next launch—and, it hopes, ...
Nasdaq

New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data to support the consistent, long-term benefits of treatment with TECFIDERA® (dimethyl fumarate) over ...
TheStreet.com

Biogen Loses Court Decision to Mylan Over Multiple Sclerosis Drug

View post: AT&T follows T-Mobile with bold move to win back customers View post: After Rate Cut, Fed Chair Jerome Powell Credits Automation and AI For Contributing to This "Structural" Boom in the U.S ...
Law

'Unfair Business Practices'?: Lawsuits Allege Big Pharma Multiple Sclerosis Drug Monopoly

"Biogen's anticompetitive conduct, and the PBMs' participation in it, delayed and substantially diminished the sale of generic Tecfidera in the United States, and unlawfully enabled Biogen to sell ...
MarketWatch

‘Grandma and grandpa aren’t going to figure this one out.’ Prescription-drug savings vanish in the Medicare shuffle

For Medicare patients struggling to afford the Biogen BIIB multiple sclerosis drug Tecfidera, the arrival last year of far cheaper generic competitors should have been great news. Instead, it has ...
The Boston Globe

Biogen suffers setback in patent dispute over its top-selling drug

A federal court sided with the generic drug maker Mylan Pharmaceuticals on Thursday in a patent dispute over Biogen’s blockbuster multiple sclerosis drug Tecfidera, sending shares of the Cambridge ...
The Boston Globe

Biogen loses bid to revive patent on Tecfidera MS drug

Biogen lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, which accounted for more than a quarter of the company’s revenue before generic versions ...